Trial Profile
Experience of the Patient Treated With Trastuzumab (Herceptin) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Oct 2016 Primary endpoint (score of fatigue) has not been met, according to results presented at the 41st European Society for Medical Oncology Congress .
- 11 Oct 2016 Results, presented at the 41st European Society for Medical Oncology Congress.
- 20 Jul 2016 Status changed from active, no longer recruiting to completed.